Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. ROIV
2. HUVR:IN
3. TAP
4. DELL
5. LAD
6. ASML
7. NVS
8. TTE
9. ANET
10. NKE

Go back to Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Stifel Reiterates Buy Rating on Pliant Therapeutics (PLRX)

August 8, 2024 9:30 AM EDT

Stifel analyst Alex Thompson reiterated a Buy rating and $32.00 price target on Pliant Therapeutics (NASDAQ: PLRX).

The analyst comments "We remain Buy Rated on PLRX following their 2Q24 update. The Ph2/3 BEACON-IPF trial remains the key driver for shares over the next 12-18... More